U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 216660
Company: AMYLYX
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
RELYVRIO SODIUM PHENYLBUTYRATE; TAURURSODIOL 3GM/PACKET; 1GM/PACKET FOR SUSPENSION;ORAL Discontinued None Yes No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
09/29/2022 ORIG-1 Approval Type 1 - New Molecular Entity PRIORITY; Orphan Label (PDF)
Letter (PDF)
Review
Summary Review (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/216660Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216660Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216660Orig1s000SumR.pdf
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
09/29/2022 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf
Back to Top